Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Bioavailability of JNJ-63623872 (Pimodivir) in Healthy Adults
NCT02860806Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pimodivir in Influenza A virus infection (IAV) (10 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Analyte Concentration up to 10 days, Fluctuation Index up to 10 days and 16 more. Started Aug 2016; status: completed.
02
Drugs
pimodivir
03
Conditions
Influenza A virus infection (IAV)
Beyond the preview
Go deeper on NCT02860806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02860806.